HEALTH

FDA Declines Approval of MDMA-Assisted Therapy for PTSD

The US Food and Drug Administration (FDA) has declined to approve a treatment that combines the psychedelic drug midomafetamine with assisted therapy (MDMA-AT) for the treatment of posttraumatic stress disorder (PTSD).  In a statement, drug manufacturer Lykos Therapeutics said the agency had issued a complete response letter…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button